RASSF1A promoter methylation is speculated to influence drug sensitivity of tumors like non small cell lung carcinoma [63], esophageal squamous carcinoma tumorigenesis [64], breast cancer patients [65]. The gene discussed is RASSF1; the disease is non-small cell lung carcinoma.